Wet AMD drug enters Phase I trial

Palomid 529 (P529) is to enter its Phase I trial in patients with AMD. A Phase I Open-Label Study to Investigate the Safety, Tolerability and Pharmacokinetic Profile of Single Intravitreal and Subconjunctival Doses of Palomid 529 in Patients with Advanced Neovascular Age-Related Macular Degeneration will according to Paloma Pharmaceuticals, be a dose-ranging study for safety but will also have an objective measure for efficacy.

“As P529 is an inhibitor of both the TORC1 and TORC2 arms ultimately controlling the PI3K/Akt/mTOR pathway it would be expected to have broad activity as an anti-angiogenic agent and further inhibit vascular permeability, two aspects that make a compelling story for clinical studies in AMD. We look forward to working with Paloma Pharmaceuticals on this interesting approach to wet AMD,” said Dr Jeffrey Heier, M.D., principal investigator of the study with Ophthalmic Consultants of Boston.